
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc is positioned for solid revenue growth, driven by accelerated market share gains in minimally invasive glaucoma surgery (MIGS) and quicker adoption of its TearCare product. The company’s Surgical Glaucoma segment is expected to sustain growth in line with the overall MIGS market, reinforcing its potential for future success. Additionally, improved earnings per share (EPS) projections reflect a positive trend towards profitability, with estimates for 2025 and 2026 indicating a decrease in losses from previous forecasts.
Bears say
Sight Sciences Inc. has reiterated its 2025 revenue guidance of $72-76 million, indicating persistent challenges, particularly with expected mid-single digit percentage declines in Surgical Glaucoma revenue for the third quarter of 2025. The company faces significant risks, including intensified competition in minimally invasive glaucoma surgery (MIGS) and slow advancements in securing insurance coverage for its TearCare System, along with ongoing concerns about high cash burn rates. Additionally, while management has lowered its adjusted operating expense guidance for 2025 from $101-105 million to $95-99 million, the anticipated savings from workforce reductions highlight the need to improve financial efficiency amidst these challenges.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares